Review on a Novel Advancement in Dry Powder Inhaler
DOI:
https://doi.org/10.22270/ajprd.v11i3.1268Keywords:
Dry Power Inhaler, Lung Deposition, Low Variability, Enzymatic Degradation.Abstract
Human health management has always been the focus area of medical practitioners across the world. Health is maintained with the right kind of food intake, regular exercise, and remedial medications whenever and wherever necessary. Medications have been an integral part of human health management and improvement ever since. Along with medications, the right kind of drug delivery mechanism plays a crucial role in the efficacy of the medications. Dry powder inhalers (DPI) are one of the most efficient and advanced targeted drug delivery mechanisms. Currently, a wide range of inhaler devices are available on the market for pulmonary drug delivery with a view to maximising drug delivery with low variability compared to other drug delivery systems. Compared to other oral, topical, and parenteral drug delivery methods, DPI's efficiency is manifold. It has varied benefits, like rapid drug absorption due to the high density of blood vessels and the large surface area of the lungs (high lung deposition); the lungs have low enzymatic activity, so this route has a minimum risk for enzymatic degradation. Faster absorption, maximum efficiency, site target, minimum wastage, user-friendly, etc. Historically, DPIs were used only for respiratory-related ailments. But now, due to their better utility value, DPIs are also used in other maladies treatments.
This research paper focuses on various advancements in the field of dry powder inhalers (DPIs), their advanced manufacturing techniques, challenges, and the evolution of technology that help maintain their versatility, stability, and reliability.
Downloads
Download data is not yet available.
References
1. H. Chrystyn et al. The Diskus TM: A review of its position among dry powder inhaler devices, International journal of clinical pharmacy, doi: 10.1111/j.1742-1241.2007.01382. 10 June 2007, 61, 6, 1022–1036.
2. Birendrachaurasiya and You-yang zhao et al. Dry powder for pulmonary delivery: A comprehensive review, multidisciplinary digital publishing Institute pharmaceutics 2021 , https://dx.doi.org/10.3390/pharmaceutics13010031.
3. Mahavir B. chaugule, bijay K. Padhi, kaustubh A. Ji nturkar and ambikanandanmisra et al. Development of dry powder inhaler recent patent on drug delivery and formulation, bentham science publisher Ltd. 2007-1.
4. N. deepthi, S. Ramkanth, S. Angalaparameswari, Mohamed saleem, K. Prakash et al. Dry powder inhaler- an overview, international journal for pharmaceutical research scholars, Int. J. Res. Pharm. Sci. Vol-1, issue-1, 2010.
5. Nazrulislaam, Ellen gladki et al. Dry powder inhalers – A review of device reliability and innovation. International journal of pharmaceutics,Doi:10.1016/j.ijpharm.2008.04.044
6. Paul J. Atkins et al. Dry powder inhalers: an overview. Respiratory care October 2005, Vol-50, No. 10.
7. Newman SP, moren F, Crompton GK. Et al. A new concept in inhalation therapy. Londan : medicom;1987.
8. Chan HK. Et al. Inhalation drug delivery devices and emerging technologies. Expert opinion ther patents 2003; 13(9): 1333-1343.
9. Saleem and smyth et al. Micro ionization of a soft material: air-jet and micro-ball milling. American Association of Pharmaceutical Scientists, pharma scitech, 2010,1642–1649.
10. Gradon, L.; Sosnowski, T.R. et al. Formation of particles for dry powder inhalers. Adv. Powder Technol. 2014, 25, 43–55.
11. Xiaojian Li, MS, Frederick G. Vogt et al. Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers, Journal of aerosol medicine and pulmonary drug delivery.
12. Xiaojian Li, MS,Frederick G. Vogt, Don Hayesand Heidi M. Mansour et al. Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. J. Aerosol Med. Pulmonary Drug Delivery. 2014, 27, 81–93.
13. Cheow, W.S.; Ng, M.L.L.; Kho, K.; Hadinoto, K. et al. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle Aggregates for inhaled drug delivery: Effect of freeze-drying adjuvants. Int. J. Pharm. 2011, 404, 289–300.
14. Maa, Y.-F.; Prestrelski, S.J. et al. Biopharmaceutical Powders Particle Formation and Formulation Considerations. Curr. Pharm. Biotechnol. 2000, 1, 283–302.
15. Esfandiari N. et al. Production of micro and nano particles of pharmaceutical by supercritical carbon dioxide. J. Supercritical Fluids 2015,100, 129–141.
16. Grenha, A.; Seijo, B.; Remuñán-López, C. et al. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 2005, 25, 427–437.
17. P.M. Young, P. Kwok, H. Adi, H.-K. Chan, D. Traini et al. Lactose composite carriers for respiratory delivery, Pharm. Res. 26 (2009) 802–810.
18. Novartis, Patient information: TOBI (TOH-bee) Podhaler (POD-hay-ler), (Access Date: 18 December 2013) 2013.
19. W.F. Tonnis, A.J. Lexmond, H.W. Frijlink, A.H. de Boer, W.L. Hinrichs et al. Devices and Formulations for pulmonary vaccination, Expert Opin. Drug Deliv. 10 (2013) 1383–1397.
20. Goren, N. Noviski, A. Avital, C. Maayan, E. Stahl, S. Godfrey, C. Springer et al. Assessment of the ability of young children to use a powder inhaler device. (Turbuhaler), Pediatr. Pulmonol. 18 (1994) 77–80.
21. P.J. Barnes et al. Distribution of receptor targets in the lung, Proc. Am. Thorac. Soc. 1(2004) 345–351. J.
22. Serra-Batlles, V. Plaza, C. Badiola, E. Morejón et al. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/ Accuhaler with Turbuhaler, J. Aerosol Med. 15 (2002) 59–64.
23. Riaz M. et al. Stability and uses of liposomes. Pak J Pharm Sci 1995;8:69–79.
24. S. Chennakesavulua,A. Mishra a, A. Sudheer b, C. Sowmyac,C. Suryaprakash Reddy c, E. Bhargav et al. Pulmonary delivery of liposomal dry powder Inhaler formulation for effective treatment of Idiopathic pulmonary fibrosis, asian journal of pharmaceutical sciences 13 (2018) 91–100.
25. Mahavir Chougule, BijayPadhi and AmbikanandanMisra et al. Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone. AAPS PharmSciTech, Vol. 9, No. 1, March 2008 (# 2007) DOI: 10.1208/s12249-007-9024-6. Received 19 August 2007; accepted 8 November 2007; published online 9 February 2008.
26. S. P. Shah and AmbikanandanMisra et al. Development of Liposomal Amphotericin B Dry Powder Inhaler Formulation. Drug Delivery, 11:247–253, 2004 Copyright C Taylor & Francis Inc. ISSN: 1071-7544 print / 1521-0464 online DOI: 10.1080/10717540490467375.
27. Mahavir Chougule, BijayPadhi and AmbikanandanMisraet al. Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary Pharmacokinetics. , International Journal of Nanomedicine, 2:4, 675-688, DOI: 10.2147/ IJN.S2.4.675 To link to this article: https://doi.org/10.2147/IJN.S2.4.675.
28. H. Yamamoto, Y. Kuno, S. Sugimoto, H. Takeuchi, Y. Kawashima, et al. Surface-modified PLGA Nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening Of the intercellular tight junctions, J. Controlled Release, 102 (2005) 373-381.
29. D. J. Singh, A. A. Lohade, J. J. Parmar, Darshana D. Hegde, P. Soni1, A. Samad, And Mala D. Menon et al. Development of Chitosan‑based Dry Powder Inhalation System of Cisplatin for Lung Cancer, Indian Journal of Pharmaceutical Sciences, November – December 2012.
30. Hui Wang; Graeme George; Selena Bartlett, Changyou Gao; Nazrul Islam et al. Nicotine Hydrogen Tartrate Loaded Chitosan Nanoparticles: Formulation, Characterization and in vitro Delivery from Dry Powder Inhaler Formulation, European Journal of Pharmaceutics and Biopharmaceutics Received Date: 3 October 2016 Revised Date: 6 December 2016 Accepted Date: 7 December 2016.
31. Steiner, S.S., et al., Method for drug delivery to the pulmonary system. 2002, Google Patents.
32. Zeng, X.M., G.P. Martin, and C. Marriott et al. Preparation and in vitro evaluation of Tetrandrine-entrapped albumin microspheres as an inhaled drug delivery system. European Journal of Pharmaceutical Sciences, 1995. 3(2): p. 87-93.
33. Sakagami, M., et al., Enhanced pulmonary absorption following aerosol Administration of mucoadhesive powder microspheres. Journal of controlled Release, 2001. 77(1): p. 117-129.
34. Ng, K.-y., et al., Alveolar macrophage cell line is not activated by exposure to Polymeric microspheres. International journal of pharmaceutics, 1998. 170(1): p. 41-49.
35. Hitendra S MahajanSadanand A Gundare et al. Preparation, characterization and pulmonary pharmacokinetics of xyloglucan microspheres as dry powder inhalation, CarbohydrPolym. 2014 Feb 15;102:529-36.Doi: 10.1016/j.carbpol.2013.11.036. Epub 2013 Dec 4.
36. Silvio Farago, Giulia Lucconi, Sara Perteghella, Barbara Vigani et al. RESEARCH ARTICLE : A dry powder formulation from silk fibroin microspheres as a topical Auto-gelling device, Pharmaceutical Development and Technology , ISSN: 1083-7450 (print), 1097-9867 (electronic), 11 March 2015.
37. RémiRosière, Matthias Van Woensel , Véronique Mathieu et al. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy, Int J Pharm. 2016 Mar 30;501(1-2):148-59.Doi: 10.1016/j.ijpharm.2016.01.073. Epub 2016 Feb 2.
38. Hitendra S Mahajan , Prashant R Mahajan et al. Development of grafted xyloglucan micelles for pulmonary delivery of curcumin: In vitro and in vivo studies, Int J BiolMacromol. 2016 Jan;82:621-7.Doi: 10.1016/j.ijbiomac.2015.09.053. Epub 2015 Sep 30.
39. Speiser, p. et al. . Poorly soluble drugs: a challenge in drug delivery. Emulsions and Nanosuspensions for the formulation of poorly soluble drugs. MedpharmScientific Publishers, Stuttgart, 1998: p. 15-28.
40. McIntire, G.L., et al., Pulmonary delivery of nanoparticles of insoluble, iodinated CT x‐ray contrast agents to lung draining lymph nodes in dogs. Journal of Pharmaceutical sciences, 1998. 87(11): p. 1466-1470.
41. Armstrong, D., et al., Poly‐(d, l‐Lactic Acid) Microspheres Incorporating Histological Dyes for Intra‐pulmonary Histopathological Investigations. Journal Of pharmacy and pharmacology, 1996. 48(3): p. 258-262.
42. Sujit Kumar Debnath et al. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide, national library of medicine, PMID: 29370192, PMCID: PMC5784924 , DOI: 10.1371/journal.pone.0190976.
43. Mohammad D. A. Muhsin, Graeme George, Kenneth Beagley et al. Effects of chemical conjugation of L-leucine to chitosan on dispersibility and controlled release of drug from a nanoparticulate dry powder inhaler formulation, 2016 American Chemical Society. Mol. Pharmaceutics 2016, 13, 5, 1455–1466, https://doi.org/10.1021/acs.molpharmaceut.5b00859.
44. MuÈller, R.H., K. MaÈder, and S. Gohla et al. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics, 2000. 50(1): p. 161-177.
45. Nan Li, Xu Li, Peng Cheng, Ping Yang et al. Preparation of Curcumin Solid Lipid Nanoparticles Loaded with Flower-Shaped Lactose for Lung Inhalation and Preliminary Evaluation of Cytotoxicity In Vitro. Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 4828169, 15 pages, 2021.https://doi.org/10.1155/2021/4828169.
46. Yan-Zhen Li , Xun Sun et al. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles, national library of medicine, Pharm Res. 2010 Sep;27(9):1977-86. doi: 10.1007/s11095-010-0201-z. Epub 2010 Jul 13. PMID: 20625801.
2. Birendrachaurasiya and You-yang zhao et al. Dry powder for pulmonary delivery: A comprehensive review, multidisciplinary digital publishing Institute pharmaceutics 2021 , https://dx.doi.org/10.3390/pharmaceutics13010031.
3. Mahavir B. chaugule, bijay K. Padhi, kaustubh A. Ji nturkar and ambikanandanmisra et al. Development of dry powder inhaler recent patent on drug delivery and formulation, bentham science publisher Ltd. 2007-1.
4. N. deepthi, S. Ramkanth, S. Angalaparameswari, Mohamed saleem, K. Prakash et al. Dry powder inhaler- an overview, international journal for pharmaceutical research scholars, Int. J. Res. Pharm. Sci. Vol-1, issue-1, 2010.
5. Nazrulislaam, Ellen gladki et al. Dry powder inhalers – A review of device reliability and innovation. International journal of pharmaceutics,Doi:10.1016/j.ijpharm.2008.04.044
6. Paul J. Atkins et al. Dry powder inhalers: an overview. Respiratory care October 2005, Vol-50, No. 10.
7. Newman SP, moren F, Crompton GK. Et al. A new concept in inhalation therapy. Londan : medicom;1987.
8. Chan HK. Et al. Inhalation drug delivery devices and emerging technologies. Expert opinion ther patents 2003; 13(9): 1333-1343.
9. Saleem and smyth et al. Micro ionization of a soft material: air-jet and micro-ball milling. American Association of Pharmaceutical Scientists, pharma scitech, 2010,1642–1649.
10. Gradon, L.; Sosnowski, T.R. et al. Formation of particles for dry powder inhalers. Adv. Powder Technol. 2014, 25, 43–55.
11. Xiaojian Li, MS, Frederick G. Vogt et al. Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers, Journal of aerosol medicine and pulmonary drug delivery.
12. Xiaojian Li, MS,Frederick G. Vogt, Don Hayesand Heidi M. Mansour et al. Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. J. Aerosol Med. Pulmonary Drug Delivery. 2014, 27, 81–93.
13. Cheow, W.S.; Ng, M.L.L.; Kho, K.; Hadinoto, K. et al. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle Aggregates for inhaled drug delivery: Effect of freeze-drying adjuvants. Int. J. Pharm. 2011, 404, 289–300.
14. Maa, Y.-F.; Prestrelski, S.J. et al. Biopharmaceutical Powders Particle Formation and Formulation Considerations. Curr. Pharm. Biotechnol. 2000, 1, 283–302.
15. Esfandiari N. et al. Production of micro and nano particles of pharmaceutical by supercritical carbon dioxide. J. Supercritical Fluids 2015,100, 129–141.
16. Grenha, A.; Seijo, B.; Remuñán-López, C. et al. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 2005, 25, 427–437.
17. P.M. Young, P. Kwok, H. Adi, H.-K. Chan, D. Traini et al. Lactose composite carriers for respiratory delivery, Pharm. Res. 26 (2009) 802–810.
18. Novartis, Patient information: TOBI (TOH-bee) Podhaler (POD-hay-ler), (Access Date: 18 December 2013) 2013.
19. W.F. Tonnis, A.J. Lexmond, H.W. Frijlink, A.H. de Boer, W.L. Hinrichs et al. Devices and Formulations for pulmonary vaccination, Expert Opin. Drug Deliv. 10 (2013) 1383–1397.
20. Goren, N. Noviski, A. Avital, C. Maayan, E. Stahl, S. Godfrey, C. Springer et al. Assessment of the ability of young children to use a powder inhaler device. (Turbuhaler), Pediatr. Pulmonol. 18 (1994) 77–80.
21. P.J. Barnes et al. Distribution of receptor targets in the lung, Proc. Am. Thorac. Soc. 1(2004) 345–351. J.
22. Serra-Batlles, V. Plaza, C. Badiola, E. Morejón et al. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/ Accuhaler with Turbuhaler, J. Aerosol Med. 15 (2002) 59–64.
23. Riaz M. et al. Stability and uses of liposomes. Pak J Pharm Sci 1995;8:69–79.
24. S. Chennakesavulua,A. Mishra a, A. Sudheer b, C. Sowmyac,C. Suryaprakash Reddy c, E. Bhargav et al. Pulmonary delivery of liposomal dry powder Inhaler formulation for effective treatment of Idiopathic pulmonary fibrosis, asian journal of pharmaceutical sciences 13 (2018) 91–100.
25. Mahavir Chougule, BijayPadhi and AmbikanandanMisra et al. Development of Spray Dried Liposomal Dry Powder Inhaler of Dapsone. AAPS PharmSciTech, Vol. 9, No. 1, March 2008 (# 2007) DOI: 10.1208/s12249-007-9024-6. Received 19 August 2007; accepted 8 November 2007; published online 9 February 2008.
26. S. P. Shah and AmbikanandanMisra et al. Development of Liposomal Amphotericin B Dry Powder Inhaler Formulation. Drug Delivery, 11:247–253, 2004 Copyright C Taylor & Francis Inc. ISSN: 1071-7544 print / 1521-0464 online DOI: 10.1080/10717540490467375.
27. Mahavir Chougule, BijayPadhi and AmbikanandanMisraet al. Nano-liposomal dry powder inhaler of tacrolimus: Preparation, characterization, and pulmonary Pharmacokinetics. , International Journal of Nanomedicine, 2:4, 675-688, DOI: 10.2147/ IJN.S2.4.675 To link to this article: https://doi.org/10.2147/IJN.S2.4.675.
28. H. Yamamoto, Y. Kuno, S. Sugimoto, H. Takeuchi, Y. Kawashima, et al. Surface-modified PLGA Nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening Of the intercellular tight junctions, J. Controlled Release, 102 (2005) 373-381.
29. D. J. Singh, A. A. Lohade, J. J. Parmar, Darshana D. Hegde, P. Soni1, A. Samad, And Mala D. Menon et al. Development of Chitosan‑based Dry Powder Inhalation System of Cisplatin for Lung Cancer, Indian Journal of Pharmaceutical Sciences, November – December 2012.
30. Hui Wang; Graeme George; Selena Bartlett, Changyou Gao; Nazrul Islam et al. Nicotine Hydrogen Tartrate Loaded Chitosan Nanoparticles: Formulation, Characterization and in vitro Delivery from Dry Powder Inhaler Formulation, European Journal of Pharmaceutics and Biopharmaceutics Received Date: 3 October 2016 Revised Date: 6 December 2016 Accepted Date: 7 December 2016.
31. Steiner, S.S., et al., Method for drug delivery to the pulmonary system. 2002, Google Patents.
32. Zeng, X.M., G.P. Martin, and C. Marriott et al. Preparation and in vitro evaluation of Tetrandrine-entrapped albumin microspheres as an inhaled drug delivery system. European Journal of Pharmaceutical Sciences, 1995. 3(2): p. 87-93.
33. Sakagami, M., et al., Enhanced pulmonary absorption following aerosol Administration of mucoadhesive powder microspheres. Journal of controlled Release, 2001. 77(1): p. 117-129.
34. Ng, K.-y., et al., Alveolar macrophage cell line is not activated by exposure to Polymeric microspheres. International journal of pharmaceutics, 1998. 170(1): p. 41-49.
35. Hitendra S MahajanSadanand A Gundare et al. Preparation, characterization and pulmonary pharmacokinetics of xyloglucan microspheres as dry powder inhalation, CarbohydrPolym. 2014 Feb 15;102:529-36.Doi: 10.1016/j.carbpol.2013.11.036. Epub 2013 Dec 4.
36. Silvio Farago, Giulia Lucconi, Sara Perteghella, Barbara Vigani et al. RESEARCH ARTICLE : A dry powder formulation from silk fibroin microspheres as a topical Auto-gelling device, Pharmaceutical Development and Technology , ISSN: 1083-7450 (print), 1097-9867 (electronic), 11 March 2015.
37. RémiRosière, Matthias Van Woensel , Véronique Mathieu et al. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy, Int J Pharm. 2016 Mar 30;501(1-2):148-59.Doi: 10.1016/j.ijpharm.2016.01.073. Epub 2016 Feb 2.
38. Hitendra S Mahajan , Prashant R Mahajan et al. Development of grafted xyloglucan micelles for pulmonary delivery of curcumin: In vitro and in vivo studies, Int J BiolMacromol. 2016 Jan;82:621-7.Doi: 10.1016/j.ijbiomac.2015.09.053. Epub 2015 Sep 30.
39. Speiser, p. et al. . Poorly soluble drugs: a challenge in drug delivery. Emulsions and Nanosuspensions for the formulation of poorly soluble drugs. MedpharmScientific Publishers, Stuttgart, 1998: p. 15-28.
40. McIntire, G.L., et al., Pulmonary delivery of nanoparticles of insoluble, iodinated CT x‐ray contrast agents to lung draining lymph nodes in dogs. Journal of Pharmaceutical sciences, 1998. 87(11): p. 1466-1470.
41. Armstrong, D., et al., Poly‐(d, l‐Lactic Acid) Microspheres Incorporating Histological Dyes for Intra‐pulmonary Histopathological Investigations. Journal Of pharmacy and pharmacology, 1996. 48(3): p. 258-262.
42. Sujit Kumar Debnath et al. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of Prothionamide, national library of medicine, PMID: 29370192, PMCID: PMC5784924 , DOI: 10.1371/journal.pone.0190976.
43. Mohammad D. A. Muhsin, Graeme George, Kenneth Beagley et al. Effects of chemical conjugation of L-leucine to chitosan on dispersibility and controlled release of drug from a nanoparticulate dry powder inhaler formulation, 2016 American Chemical Society. Mol. Pharmaceutics 2016, 13, 5, 1455–1466, https://doi.org/10.1021/acs.molpharmaceut.5b00859.
44. MuÈller, R.H., K. MaÈder, and S. Gohla et al. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. European journal of pharmaceutics and biopharmaceutics, 2000. 50(1): p. 161-177.
45. Nan Li, Xu Li, Peng Cheng, Ping Yang et al. Preparation of Curcumin Solid Lipid Nanoparticles Loaded with Flower-Shaped Lactose for Lung Inhalation and Preliminary Evaluation of Cytotoxicity In Vitro. Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 4828169, 15 pages, 2021.https://doi.org/10.1155/2021/4828169.
46. Yan-Zhen Li , Xun Sun et al. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles, national library of medicine, Pharm Res. 2010 Sep;27(9):1977-86. doi: 10.1007/s11095-010-0201-z. Epub 2010 Jul 13. PMID: 20625801.
Published
2023-06-21
How to Cite
Bhagat, P. D., Redasani, V. kumar, D. Jadhav, P., Velha, A. B., & Mahadik, R. A. (2023). Review on a Novel Advancement in Dry Powder Inhaler. Asian Journal of Pharmaceutical Research and Development, 11(3), 136–142. https://doi.org/10.22270/ajprd.v11i3.1268
Issue
Section
Review Articles
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.